- ≥99% by HPLC per component; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
CJC-1295 (No DAC) + Ipamorelin
GHRH analogue and selective ghrelin-receptor agonist co-lyophilized in one vial
- FormCo-lyophilized powder, sealed glass vial
- Mol. weightCJC-1295 (No DAC): 3367.93 g/mol · Ipamorelin: 711.85 g/mol
- Research areasPulsatile GH release, somatotroph signalling, IGF-1 axis, body-composition and sleep-architecture models
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
This blend places two growth-hormone secretagogues with different mechanisms into a single co-lyophilized vial. CJC-1295 without DAC — also catalogued as Modified GRF (1-29) — is a 29-residue analogue of growth hormone-releasing hormone carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage. It engages the GHRH receptor on somatotrophs. Ipamorelin is a pentapeptide agonist at the growth hormone secretagogue receptor, the same receptor ghrelin acts on, and is the most selective of the commonly studied GHRPs.
Specifications
Identity
- CAS number
- CJC-1295 (No DAC): 863288-34-0 · Ipamorelin: 170851-70-4
- Molecular formula
- CJC-1295 (No DAC): C152H252N44O42 · Ipamorelin: C38H49N9O5
- Molecular weight
- CJC-1295 (No DAC): 3367.93 g/mol · Ipamorelin: 711.85 g/mol
- Peptide class
- GHRH analogue combined with a growth hormone secretagogue receptor agonist
Supply & purity
- Form
- Co-lyophilized powder, sealed glass vial
- Purity
- ≥99% by HPLC per component; lot-matched COA available
- Available sizes
- 10 mg (5 mg/5 mg), 20 mg (10 mg/10 mg)
- Solubility
- Bacteriostatic water
Additional detail
- Blend ratio
- 1:1 CJC-1295 (No DAC) to Ipamorelin
- CJC-1295 sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
- Ipamorelin sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Research areas
- Pulsatile GH release, somatotroph signalling, IGF-1 axis, body-composition and sleep-architecture models
- Storage
- Lyophilized: −20 °C, protected from light and moisture. Reconstituted: 2–8 °C, use within the study window.
Questions about CJC-1295 (No DAC) + Ipamorelin
What is the difference between CJC-1295 with and without DAC?
The DAC version carries a Drug Affinity Complex maleimide that binds serum albumin, extending its presence for days. The No DAC form used in this blend omits that group, so it acts briefly and produces a discrete pulse. Researchers studying pulsatility choose the No DAC form for exactly that reason.
Is each component tested separately?
Yes. Purity and identity are established for each peptide by an independent laboratory using HPLC and mass spectrometry before blending, and the resulting certificate of analysis is matched to the lot number printed on your vial. It is available on request.
What does 10 mg (5/5) mean?
It is the total peptide mass in the vial, split evenly between the two components — 5 mg of CJC-1295 (No DAC) and 5 mg of Ipamorelin. The 20 mg vial contains 10 mg of each. Both are dried together as one cake, so reconstitution yields a fixed 1:1 solution.
Why is Ipamorelin used rather than an older GHRP?
Ipamorelin was characterised as unusually selective for the growth hormone secretagogue receptor, releasing growth hormone with far less effect on cortisol, ACTH and prolactin than GHRP-6 or GHRP-2. In study designs where those hormones would confound the endpoint, that selectivity matters.
Related
